The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index; 1 of the 121 sources its claims cite were checked for support.
p53 at a glance
Open accessAbstract
Since its discovery in 1979, the role of the p53 protein in cancer has been studied intensively (Levine and Oren, 2009). p53 is a crucial tumor suppressor, long-recognized to suppress cancer through the induction of cell-cycle-arrest or apoptosis programs in response to a plethora of different cellular stress signals. Although this model paints a seemingly simple picture, the longer that p53 is studied, the more it confronts researchers with new questions about its functions and mechanisms of action. The tumor-suppressor function of p53 extends beyond the capacity to trigger cell-cycle arrest and apoptosis, and novel activities that impact tumor suppression are perpetually emerging, including the regulation of metabolism, autophagy and the oxidative status of the cell. Moreover, because it acts as a crucial node downstream of diverse stress signals, it is perhaps not surprising that p53 has been recently discovered to have broader roles in physiology and pathology. In this article and its accompanying poster, we outline the basic molecular and cellular functions of p53, describe the intricate network of p53 mediators, and provide insight into the roles of p53 in normal physiology and human disease.Analysis of human cancers reveals a fundamental role for p53 in tumor suppression. More than half of human cancers, of a wide variety of types, harbor p53 (TP53) mutations, and inheritance of a mutant p53 allele predisposes humans to the Li-Fraumeni cancer syndrome (Olivier et al., 2010). Unequivocal confirmation of the crucial role for p53 in tumor suppression was demonstrated by the completely penetrant cancer phenotype of p53-null mice (Kenzelmann Broz and Attardi, 2010). p53 restricts tumor development by serving as a sensor of cellular stress, responding to diverse signals, including DNA damage, hypoxia, oncogene expression, nutrient deprivation and ribosome dysfunction, and limiting the propagation of cells under these adverse conditions (Vousden and Prives, 2009). In metazoans, an ancestral function of p53 is thought to be its ability to trigger programmed cell death (also known as apoptosis) in response to DNA damage, as a measure to preserve the integrity of the germ line (Junttila and Evan, 2009; Lu and Abrams, 2006; Lu et al., 2009). Subsequently, with the evolution of longer-living organisms, p53 is thought to have acquired the ability to respond to oncogenic signals, promoting apoptosis or senescence – a permanent cell-cycle-arrest response – as a safeguard against neoplasia. Thus, in cells exposed to potent stress signals, p53 drives irreversible programs of apoptosis or senescence to cull irreparably damaged or malignant cells, for the ultimate benefit of the organism (Vousden and Prives, 2009). Alternatively, under conditions of low-level stress, p53 elicits protective, pro-survival responses, such as temporary cell-cycle arrest, DNA repair and antioxidant protein production, to maintain genome integrity and viability in cells that sustain limited, reparable damage. These various responses rely on the ability of p53 to function as a transcriptional activator of a panoply of target genes, although transactivation-independent activities ascribed to p53 can also contribute to p53-mediated responses, as highlighted below.Similarly to other transcription factors, p53 has a modular protein domain structure (Joerger and Fersht, 2007; Vousden and Prives, 2009). The N-terminus of p53 comprises two transcriptional activation domains (TADs), TAD1 and TAD2, which span amino acid residues 1-40 and 40-60, respectively. These domains can independently enhance transcription of p53 target genes by recruiting histone-modifying enzymes, components of the basal transcriptional machinery and coactivator complexes, such as STAGA and Mediator (Gamper and Roeder, 2008; Joerger and Fersht, 2007). C-terminal to the transactivation domains, between residues 60-95, lies the proline-rich domain (PRD), which was originally proposed to participate in protein-protein interactions on the basis of the presence of PxxP motifs that resemble Src homology 3 (SH3)-domain-binding regions (Toledo et al., 2006; Toledo et al., 2007). However, a structural function might be the main role of this domain because knock-in mice carrying proline-to-alanine point mutations in the putative protein-protein interaction sites of this domain appear normal, whereas complete domain deletion disrupts p53 tumor-suppressor function. The central core of p53, which spans residues 100-300, comprises the DNA-binding domain that is responsible for sequence-specific binding of the protein to p53 response elements in DNA. Most cancer-associated p53 mutations are missense mutations in this domain and incapacitate DNA binding, illuminating the key importance of DNA binding for p53-mediated tumor suppression. Tumor-derived p53 mutations either alter residues that are essential for direct contact with p53 response elements (contact mutants) or impair proper folding of
Overview
CoChat Summary
TL;DR
This review summarizes p53 as a central stress-sensing tumor suppressor, covering its protein domains, transcriptional and cytoplasmic functions, regulation by MDM2/MDMX, and broader roles in physiology and disease. It emphasizes that p53 outcomes are highly context-dependent and that its biology is more complex than the canonical cell-cycle-arrest/apoptosis model.
Key findings
- p53 is mutated in more than half of human cancers of many types; inherited mutant p53 predisposes to Li-Fraumeni syndrome, and p53-null mice have a completely penetrant cancer phenotype.
- p53 has a modular domain structure: TAD1 (residues 1–40), TAD2 (40–60), proline-rich domain (60–95), DNA-binding core (100–300), tetramerization domain (325–356), and C-terminal basic domain (363–393). The six most common cancer hotspot residues are R175, G245, R248, R249, R273 and R282.
- p53 binds response elements as a tetramer, classically two half sites of RRRCWWGYYY separated by 0–13 bp. Severe stress drives apoptosis or senescence; low-level stress promotes temporary arrest, DNA repair and antioxidant responses. p53 also has cytoplasmic roles in apoptosis and autophagy, metabolic effects, and non-cell-autonomous tumor-suppressive effects.
- MDM2 and MDMX regulate p53 levels and activity. Mdm2-null mice show very early embryonic lethality that is completely rescued by p53 loss; Mdmx-null mice show p53-dependent embryonic lethality later in embryogenesis. p53 also activates MDM2 transcription, forming a negative-feedback loop.
Methods
- Narrative review article with an accompanying poster; no primary experimental design, sample or new data are reported.
- Synthesizes published literature on p53 molecular and cellular functions, its regulators, and its roles in normal physiology and human disease.
- No systematic review, meta-analysis or quantitative synthesis methods are stated.
Limitations
- The authors state that capturing the complete complexity of p53 function is beyond the scope of the article; they note omitted topics including post-translational modifications, p53 polymorphisms, p53 isoforms, and p63/p73 family interplay.
- The text highlights unresolved or controversial areas, including pro-aging versus anti-aging roles of p53 in different mouse models, the dual role of autophagy in tumor suppression, uncertainty about the full importance of the MDMX-MDM2 interaction, complexity of C-terminal lysine modifications, and unknown significance of p53 isoforms.
- Evident from the text: as a narrative review, it does not provide a systematic search strategy, quantitative synthesis, or primary data, and many conclusions rely on cited reviews and model systems.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 68 Not checked · 34 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“exciting recent findings have shown that reactivation of p53 expression in mouse models induces tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
What the sources say
- Not checked yetcites Martins et al., 2006 source
- Not checked yetcites Ventura et al., 2007 source
- Supportedcites Xue et al., 2007 source
Our copy of Xue et al. (2007) states directly that reactivating endogenous p53 in p53-deficient tumours produces complete tumour regression in vivo: the Abstract reports 'even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions', and the results describe hepatocarcinomas involuting to near-undetectable levels within 12 days of Dox-mediated p53 restoration (p. 1, Fig. 1b) and regressing after only 4 days of Dox (p. 2, Fig. 1e), including in a subcutaneous setting and in tumours co-expressing activated Akt or oncogenic K-ras. The mechanism (senescence plus innate immune clearance) is additional detail not required by the citing sentence, which is offered as one of three mouse-model citations for p53 reactivation-induced regression. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In response to sustained or severe stress signals, p53 drives irreversible apoptosis or senescence programs.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, a major component of repression probably occurs through indirect mechanisms, such as by p53-dependent activation of microRNAs or lincRNAs that repress gene expression (Guttman et al., 2009; He et al., 2007; Menendez et al., 2009; Riley et al., 2008).”
What the sources say
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“p53 also has a complex role in regulating autophagy.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The central core of p53, which spans residues 100-300, comprises the DNA-binding domain that is responsible for sequence-specific binding of the protein to p53 response elements in DNA.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims
Create a free account to see all 103 claims and to verify the 108 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Citations
Cites
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., Huarte, M., Zuk, O., Carey, B. W., Cassady, J. P., et al. (2009) · Nature · doi:10.1038/nature07672 · Cited by 4,098
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“More than half of human cancers, of a wide variety of types, harbor p53 (TP53) mutations, and inheritance of a mutant p53 allele predisposes humans to the Li-Fraumeni cancer syndrome (Olivier et al., 2010).”
BackgroundSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Indeed, exciting recent findings have shown that reactivation of p53 expression in mouse models induces tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
Backgroundp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Cited by
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Self-citationDistinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Self-citationO-GlcNAc signalling: implications for cancer cell biology
Slawson, C., & Hart, G. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3114 · Cited by 458
Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death
Vucic, D., Dixit, V. M., & Wertz, I. E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3143 · Cited by 444
The Therapeutic Target Hsp90 and Cancer Hallmarks
Miyata, Y., Nakamoto, H., & Neckers, L. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213804143725 · Cited by 352
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Mutational drivers of cancer cell migration and invasion
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M., & Denisov, E. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01149-0 · Cited by 302
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Autophagy Impairment Induces Premature Senescence in Primary Human Fibroblasts
Kang, H. T., Lee, K. B., Kim, S. Y., Choi, H. R., & Park, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023367 · Cited by 254
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
Self-citationLi, W., Li, F., Zhang, X., Lin, H.-K., & Xu, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 198
MitomiRs in human inflamm-aging: A hypothesis involving miR-181a, miR-34a and miR-146a
Rippo, M. R., Olivieri, F., Monsurrò, V., Prattichizzo, F., Albertini, M. C., & Procopio, A. D. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.03.002 · Cited by 209
Cole, A. J., Dwight, T., Gill, A. J., Dickson, K.-A., Zhu, Y., Clarkson, A., Gard, G. B., Maidens, J., Valmadre, S., Clifton-Bligh, R., et al. (2016) · Scientific Reports · doi:10.1038/srep26191 · Cited by 208
Current and upcoming therapies to modulate skin scarring and fibrosis
Coentro, J. Q., Pugliese, E., Hanley, G., Raghunath, M., & Zeugolis, D. I. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.009 · Cited by 204
Neat1 is a p53-inducible lincRNA essential for transformation suppression
Mello, S. S., Sinow, C., Raj, N., Mazur, P. K., Bieging-Rolett, K., Broz, D. K., Imam, J. F. C., Vogel, H., Wood, L. D., Sage, J., et al. (2017) · Genes & Development · doi:10.1101/gad.284661.116 · Cited by 202
Self-citationDeconstructing p53 transcriptional networks in tumor suppression
Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194
Self-citationThe two sides of chromosomal instability: drivers and brakes in cancer
Hosea, R., Hillary, S., Naqvi, S., Wu, S., & Kasim, V. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01767-7 · Cited by 189
A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179
Self-citationDNA repair processes are critical mediators of p53-dependent tumor suppression
Janic, A., Valente, L. J., Wakefield, M. J., Di Stefano, L., Milla, L., Wilcox, S., Yang, H., Tai, L., Vandenberg, C. J., Kueh, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0043-5 · Cited by 179
p53 and mitochondrial function in neurons
Wang, D. B., Kinoshita, C., Kinoshita, Y., & Morrison, R. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.015 · Cited by 167
Exploring the multiple roles of guardian of the genome: P53
Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 173
Cell death pathways of particulate matter toxicity
Peixoto, M. S., de Oliveira Galvão, M. F., & Batistuzzo de Medeiros, S. R. (2017) · Chemosphere · doi:10.1016/j.chemosphere.2017.08.076 · Cited by 172
Span, P. N., & Bussink, J. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.002 · Cited by 163
p53-Mediated Molecular Control of Autophagy in Tumor Cells
Mrakovcic, M., & Fröhlich, L. (2018) · Biomolecules · doi:10.3390/biom8020014 · Cited by 156
Bettermann, K., Benesch, M., Weis, S., & Haybaeck, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.036 · Cited by 168
p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR)
Maor-Nof, M., Shipony, Z., Lopez-Gonzalez, R., Nakayama, L., Zhang, Y.-J., Couthouis, J., Blum, J. A., Castruita, P. A., Linares, G. R., Ruan, K., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.025 · Cited by 160
Self-citationToufektchan, E., & Toledo, F. (2018) · Cancers · doi:10.3390/cancers10050135 · Cited by 146
Dutta, S., Warshall, C., Bandyopadhyay, C., Dutta, D., & Chandran, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097580 · Cited by 146
Molecular basis of organ fibrosis: Potential therapeutic approaches
Ghosh, A. K., Quaggin, S. E., & Vaughan, D. E. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213489441 · Cited by 142
Oxidative Stress in Stem Cell Aging
Chen, F., Liu, Y., Wong, N.-K., Xiao, J., & So, K. (2017) · Cell Transplantation · doi:10.1177/0963689717735407 · Cited by 140
The regulatory roles of p53 in cardiovascular health and disease
Men, H., Cai, H., Cheng, Q., Zhou, W., Wang, X., Huang, S., Zheng, Y., & Cai, L. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03694-6 · Cited by 137
Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer
Bell, E. S., Shah, P., Zuela-Sopilniak, N., Kim, D.-S., Varlet, A., Morival, J. L. P., McGregor, A., Isermann, P., Davidson, P. M., Elacqua, J. J., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02420-9 · Cited by 138
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT
Leszczyńska, K. B., Foskolou, I. P., Abraham, A., Anbalagan, S., Tellier, C., Haider, S. A., Span, P. N., O’Neill, E. E., Buffa, F. M., & Hammond, E. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80402 · Cited by 138
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129
Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer
Liu, B., Wen, X., & Cheng, Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.422 · Cited by 130
Mitochondrial dynamics and cancer
Maycotte, P., Marín‐Hernández, Á., Goyri-Aguirre, M., Anaya-Ruíz, M., Reyes‐Leyva, J., & Cortés-Hernández, P. (2017) · Tumor Biology · doi:10.1177/1010428317698391 · Cited by 125
Cai, C., Ashktorab, H., Pang, X., Zhao, Y., Sha, W., Liu, Y., & Gu, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029750 · Cited by 111
Colorectal serrated pathway cancers and precursors
O’Brien, M. J., Zhao, Q., & Yang, S. (2014) · Histopathology · doi:10.1111/his.12564 · Cited by 112
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 107
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
Herrero, A. B., Rojas, E. A., Misiewicz-Krzemińska, I., Krzemiński, P., & Gutierrez, N. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122003 · Cited by 106
Dehhaghi, M., Panahi, H. K. S., Heng, B., & Guillemin, G. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.562812 · Cited by 105
Do Mutations Turn p53 into an Oncogene?
Pitolli, C., Wang, Y., Mancini, M., Shi, Y., Melino, G., & Amelio, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246241 · Cited by 100
p53, a translational regulator: contribution to its tumour-suppressor activity
Marcel, V., Catez, F., & Diaz, J. (2015) · Oncogene · doi:10.1038/onc.2015.25 · Cited by 95
Wink, S., Hiemstra, S. W., Huppelschoten, S., Danen, E. H. J., Niemeijer, M., Hendriks, G., Vrieling, H., Herpers, B., & van de Water, B. (2014) · Chemical Research in Toxicology · doi:10.1021/tx4004038 · Cited by 95
Mutant Mice Lacking the p53 C-Terminal Domain Model Telomere Syndromes
Simeonova, I., Jaber, S., Drašković, I., Bardot, B., Fang, M., Bouarich-Bourimi, R., Lejour, V., Charbonnier, L., Soudais, C., Bourdon, J., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.028 · Cited by 93
Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., & Attardi, L. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111245108 · Cited by 91
Self-citationHsp90: Friends, clients and natural foes
Verma, S., Goyal, S., Jamal, S., Singh, A. P., & Grover, A. (2016) · Biochimie · doi:10.1016/j.biochi.2016.05.018 · Cited by 91
Rahman, N., Khan, H. Z., Zia, A., Khan, A., Fakhri, S., Aschner, M., Gul, K., & Saso, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111315 · Cited by 87
Nelson, L. E., Valentine, R. J., Cacicedo, J. M., Gauthier, M., Ido, Y., & Ruderman, N. B. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2011 · Cited by 81
Rizzi, V., Gubitosa, J., Fini, P., & Cosma, P. (2021) · Cosmetics · doi:10.3390/cosmetics8030066 · Cited by 107
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, Ł., Kocik-Krol, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Głubisz, A., & Holak, T. A. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 78
Mirzayans, R., Andrais, B., Kumar, P., & Murray, D. L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050708 · Cited by 76
Jiang, D., LaGory, E. L., Brož, D. K., Bieging-Rolett, K. T., Brady, C. A., Link, N., Abrams, J., Giaccia, A. J., & Attardi, L. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.043 · Cited by 75
Self-citationCubillos‐Rojas, M., Amair‐Pinedo, F., Peiró‐Jordán, R., Bartrons, R., Ventura, F., & Rosa, J. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.527978 · Cited by 74
Bhattacharya, S., Chaum, E., Johnson, D. A., & Johnson, L. R. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10495 · Cited by 81
The p53 control of apoptosis and proliferation: lessons from Drosophila
Mollereau, B., & Ma, D. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1035-7 · Cited by 73
Synthetic memory circuits for tracking human cell fatePreprint
Burrill, D. R., Inniss, M. C., Boyle, P. M., & Silver, P. A. (2012) · Genes & Development · doi:10.1101/gad.189035.112 · Cited by 73
Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis.
Lee, C., Blum, J. M., & Kirsch, D. G. (2013) · PubMed · Cited by 72
Jiang, H., Ma, N., Shang, Y., Zhou, W., Chen, T., Guan, D., Li, J., Wang, J., Zhang, E., Feng, Y., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.156 · Cited by 72
The roles and mechanisms of G3BP1 in tumour promotion
Zhang, C.-H., Wang, J., Cai, M., Shao, R., Liu, H., & Zhao, W. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1523415 · Cited by 70
The Viral Interferon Regulatory Factors of KSHV: Immunosuppressors or Oncogenes?
Jacobs, S. R., & Damania, B. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00019 · Cited by 72
Not all p53 gain-of-function mutants are created equal
Mello, S. S., & Attardi, L. D. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.53 · Cited by 69
Self-citationPotent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
Her, N.-G., Oh, J.-W., Oh, Y. J., Han, S., Cho, H. J., Lee, Y., Ryu, G. H., & Nam, D.-H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0825-1 · Cited by 68
Chollat-Namy, M., Safta, T. B., Haferssas, D., Meurice, G., Chouaïb, S., & Thiery, J. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1950-1 · Cited by 68
Vecchioli, S. F., Micheli, L., Saraulli, D., Ceccarelli, M., Cannas, S., Scardigli, R., Leonardi, L., Cinà, I., Costanzi, M., Ciotti, M. T., et al. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00124 · Cited by 67
DBC1 Functions as a Tumor Suppressor by Regulating p53 Stability
Qin, B., Minter‐Dykhouse, K., Yu, J., Zhang, J., Liu, T., Zhang, H., Lee, S., Kim, J.-J., Wang, L., & Lou, Z. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.066 · Cited by 66
Illuminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 65
Self-citationmicroRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network
Hoffman, Y., Pilpel, Y., & Oren, M. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju020 · Cited by 68
Structural and Drug Targeting Insights on Mutant p53
Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 64
The New Faces of Endocytosis in Signaling
Hupalowska, A., & Miączyńska, M. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01249.x · Cited by 61
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins
Buuh, Z. Y., Lyu, Z., & Wang, R. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01817 · Cited by 63
p53 Requires an Intact C-Terminal Domain for DNA Binding and Transactivation
Kim, H., Kim, K., Choi, J., Heo, K., Baek, H. J., Roeder, R. G., & An, W. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.001 · Cited by 50
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
Wallis, B., Bowman, K. E. R., Lu, P., & Lim, C. S. (2023) · Biomolecules · doi:10.3390/biom13010159 · Cited by 59
Gao, L., Chen, M., Ouyang, Y., Li, R., Zhang, X., Gao, X., Lin, S., & Wang, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.059 · Cited by 59
Hepatocellular Carcinoma and Chemotherapy: The Role of p53
Brito, A., Abrantes, A. M., Pinto-Costa, C., Gomes, A. R., Mamede, A. C., Casalta‐Lopes, J., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Tralhão, J. G., & Botelho, M. F. (2012) · Chemotherapy · doi:10.1159/000343656 · Cited by 58
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 58
P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage
Lin, R., Ho, C.-J., Chen, H.-W., Pao, Y., Chen, L.-E., Yang, M.-C., Huang, S., Wang, S., Chen, C., & Wang, C. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1520565 · Cited by 58
Gupta, K., Thakur, V. S., Bhaskaran, N., Nawab, A., Babcook, M. A., Jackson, M. W., & Gupta, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052572 · Cited by 57
Genes and Longevity of Lifespan
Bin-Jumah, M. N., Nadeem, M. S., Gilani, S. J., Al-Abbasi, F. A., Ullah, I., Alzarea, S. I., Ghoneim, M. M., Alshehri, S., Ud-Din, A., Murtaza, B. N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031499 · Cited by 66
Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles
Yalçın, M., Lin, H., Sudha, T., Bharali, D. J., Meng, R., Tang, H.-Y., Davis, F. B., Stain, S. C., Davis, P. J., & Mousa, S. A. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0137-y · Cited by 55
Zheng, J., Zhuo, L., Ran, D., Ma, Y., Luo, T., Zhao, H., Song, R., Zou, H., Zhu, J., Gu, J., et al. (2020) · Toxicology · doi:10.1016/j.tox.2020.152611 · Cited by 53
Wan, C., Ma, X., Shi, S., Zhao, J., Nie, X., Han, J., Xiao, J., Wang, X., Jiang, S., & Jiang, J. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.10.013 · Cited by 52
Eleftheriadis, T., Pissas, G., Antoniadi, G., Spanoulis, A., Liakopoulos, V., & Stefanidis, I. (2014) · International Immunology · doi:10.1093/intimm/dxu077 · Cited by 52
Is there a biological cost of protein disorder? Analysis of cancer-associated mutations
Pajkos, M., Mészáros, B., Simon, I., & Dosztányi, Z. (2011) · Molecular BioSystems · doi:10.1039/c1mb05246b · Cited by 51
Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China
Xia, Y., Li, X., & Sun, W. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200731003206 · Cited by 51
Mapping the p53 transcriptome universe using p53 natural polymorphs
Wang, B., Niu, D., Lam, T. H., Xiao, Z., & Ren, E. C. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.132 · Cited by 50
An Update on MDMX and Dual MDM2/X Inhibitors
Espadinha, M., Barcherini, V., Lopes, E. A., & Santos, M. M. M. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180604080119 · Cited by 50
Drosophila p53 integrates the antagonism between autophagy and apoptosis in response to stress
Robin, M., Issa, A.-R., Santos, C. C., Napoletano, F., Petitgas, C., Chatelain, G., Ruby, M., Walter, L., Birman, S., Domingos, P. M., et al. (2018) · Autophagy · doi:10.1080/15548627.2018.1558001 · Cited by 50
Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V., Tsogka, K., Sounidaki, M., & Stefanidis, I. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2547 · Cited by 47
Li, X.-B., Jiao, S., Sun, H., Xue, J., Zhao, W.-T., Fan, L., Wu, G., & Fang, J. S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.05.025 · Cited by 47
Dapagliflozin Prevents High-Glucose-Induced Cellular Senescence in Renal Tubular Epithelial Cells
Eleftheriadis, T., Pissas, G., Filippidis, G., Efthymiadi, M., Liakopoulos, V., & Stefanidis, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416107 · Cited by 46
Regulation of myo-inositol biosynthesis by p53-ISYNA1 pathway
Koguchi, T., Tanikawa, C., Mori, J., Kojima, Y., & Matsuda, K. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3456 · Cited by 47
Is p53 Involved in Tissue‐Specific Insulin Resistance Formation?
Strycharz, J., Drzewoski, J., Szemraj, J., & Śliwińska, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9270549 · Cited by 47
Wilson disease: At the crossroads between genetics and epigenetics—A review of the evidence
Kieffer, D. A., & Medici, V. (2017) · Liver Research · doi:10.1016/j.livres.2017.08.003 · Cited by 46
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Skalniak, Ł., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 45
Moonlighting in Mitosis: Analysis of the Mitotic Functions of Transcription and Splicing Factors
Somma, M. P., Andreyeva, E. N., Pavlova, G. A., Pellacani, C., Bucciarelli, E., Popova, J. V., Bonaccorsi, S., Pindyurin, A. V., & Gatti, M. (2020) · Cells · doi:10.3390/cells9061554 · Cited by 44
Characterization of p53 expression in rainbow trout
Liu, M., Tee, C., Zeng, F., Sherry, J. P., Dixon, B., Bols, N. C., & Duncker, B. P. (2011) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2011.06.018 · Cited by 43
Genetics and genomics of breast fibroadenomas
Loke, B. N., Nasir, N. D. M., Thike, A. A., Lee, J. Y. H., Lee, C. S., Teh, B. T., & Tan, P. H. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204838 · Cited by 43
Proteasome Activation to Combat Proteotoxicity
Jones, C. L., & Tepe, J. J. (2019) · Molecules · doi:10.3390/molecules24152841 · Cited by 43
Murray, D. L., & Mirzayans, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165766 · Cited by 43
Metadata
- Authors
- Brady, C. A., & Attardi, L. D.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Attardi, Laura D.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2010-08-01
- Volume
- 123
- Issue
- 15
- Pages
- 2527-2532
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- PMC
- PMC2912460
- OpenAlex
- W2170622332
- Cited by
- 403
- References
- 96
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 19 · 2023: 28 · 2022: 17 · 2021: 24 · 2020: 29 · 2019: 39 · 2018: 32 · 2017: 28 · 2016: 22 · 2015: 27 · 2014: 33 · 2013: 26 · 2012: 27
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Journal of Cell Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, tumor suppressor, TP53 mutation, Li-Fraumeni syndrome, cell cycle arrest, apoptosis, cellular stress response, DNA damage, hypoxia, oncogene-induced senescence, autophagy, cellular metabolism, oxidative stress, p53-null mice, cancer susceptibility
- MeSH terms
- Animals, Autophagy, Cytoplasm, Humans, Neoplasms, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-15, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-15 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.